Reply  by Benetos, Athanase et al.
e
v
a
c
p
a
h
o
v
w
l
i
a
o
*
C
D
R
*
5
N
E
R
1
2
3
4
P
a
W
p
r
c
p
w
c
a
a
f
s
T
a
t
(
8
a
v
e
a
t
p
w
t
c
i
i
a
s
e
t
i
n
i
m
B
A
c
g
p
t
m
t
l
t
r
w
*
R
*
P
E
R
1
2
R
I
d
g
t
744 Correspondence JACC Vol. 56, No. 9, 2010
August 24, 2010:742–6nd points over different periods of time. The patient in the
ignette has an estimated risk as low as 1% for a 10-year fatal
therosclerotic event, but as high as 39% for a lifetime cardiovas-
ular risk. Although this patient’s short-term risk may be low, the
atient’s lifetime risk is quite high and thus should be treated
ccordingly. Additionally, this woman could be categorized as
aving the metabolic syndrome with all 5 inclusion criteria:
besity, elevated triglycerides, low high-density lipoprotein, ele-
ated blood pressure, and abnormal fasting glucose (2).
The first goal for this patient would be lifestyle modification
ith an increase in physical activity and nutrition counseling. If the
ifestyle interventions are not sufficient to reduce her markers of
ncreased risk, it would be reasonable to consider starting her on an
ngiotensin-converting enzyme inhibitor and statin, with the goal
f preventing a first cardiovascular event and overt diabetes (3,4).
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ulse Pressure Amplification as
Predictor of Cardiovascular Risk
e read with interest the paper by Benetos et al. (1) regarding
ulse pressure amplification (PPA) as a predictor of cardiovascular
isk. We fully agree that measured PPA is an important cardiovas-
ular risk marker, because it reflects the level of central systolic/
ulse pressures for any given level of brachial pressures. However,
e would like to challenge the investigators’ conclusion that
omputed PPA based on standard risk factors, without the use of
ctual central pressure measurements, predicts cardiovascular risk
nd that “results were independent of any other confounding
actors.” The investigators generated a regression equation from a
ample of adults (n 834) to predict carotid pulse pressure (CPP). (hey identified age, sex, height, and glycemia as predictors of CPP
fter adjustment for brachial pulse pressure (BPP). The investiga-
ors present a model that predicts CPP with an impressive R2
85.8% predicted variability). However, BPP alone predicted
3.5% of the CPP variability, all the other terms providing as little
s a 2.3% increase in R2 (corresponding to 10% of the CPP
ariability not explained by BPP). The investigators provide no
vidence of the external validity of their equation, proceeding to
pply it to a large population (n  125,151). They concluded that
he estimated carotid/brachial pulse pressure ratio (C/B ratio) was
redictive of cardiovascular and all-cause death and that “results
ere independent of any other confounding factors.” To the degree
hat the estimated C/B ratio is a simple function of BPP and
lassic cardiovascular risk factors, it cannot possibly have true
ndependent value beyond those factors. The calculated C/B ratio
s necessarily correlated with BPP, hence its prognostic value after
djustment for age and sex. The marginal increase in adjusted
tandardized hazard ratios over BPP is likely due to the prognostic
ffect of body height, which is used to estimate the C/B ratio (and
herefore bears an independent association with it). Body height
tself is associated with increased cardiovascular risk (2) and was
ot included in proportional hazards models. Furthermore, the
nvestigators provided no evidence of statistical superiority of
odels including the estimated C/B ratio over those including
PP or any data reflecting actual model performance (such as
kaike’s information criteria or C-statistics). Had the investigators
ompared a model including age, sex, BPP, body height, and
lycemia with a model containing the computed C/B ratio,
rediction of cardiovascular death would have been superior with
he former.
There is a need to continue to gain understanding regarding the
echanisms and the predictive value of central hemodynamics, but
he benefit of PPA as a marker of cardiovascular risk lies in the
arge variability that cannot be predicted by standard risk factors,
herefore requiring actual assessments via pulse wave analysis,
ather than on the relatively small variability that can be predicted
ith the reported regression equation.
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eply
n the past, blood pressure measurements were devoted to the
iagnosis and treatment of threatening accidents. Currently, the
oal of measurements has changed and became prevention, but
he devices remained almost identical. For example, pulse pressure
PP) amplification (1,2), described 50 years ago, is yet poorly used
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August 24, 2010:742–6n clinical practice. The remarks of our 2 colleagues are important
n this context and should be developed.
First, it must be clarified that our equation (2) predicts carotid
P and then was used only to assess PP amplification. Second, as
reviously shown (1), PP amplification depends on most major
odifiable and nonmodifiable cardiovascular (CV) risk factors; in
he present equation, glucose was the only modifiable CV risk
actor beyond blood pressure. Third, both carotid PP and ampli-
cation provided higher predictive value than brachial PP regard-
ng CV mortality by 3% to 5% and 13% to 25%, respectively
depending on the adjusted model), whereas only 2.3% of the
ariability of predicted carotid PP was due to these factors. This is
ar less than the expected contribution of these factors (i.e., age,
ex, glucose) on CV mortality. Fourth, the equation used for
ssessing carotid PP, and thus PP amplification, was introduced in
ultivariate model further adjusting for other classical CV risk
actors: smoking, physical activity, pulse rate, cholesterol, as well as
e novo adjusted for age and sex.
Finally, the reported equation was not proposed as a substitute
f the actual assessment of central hemodynamics but as an
ndirect proof of the value of PP amplification, deriving from a
arge epidemiological study with a population of 125,151 subjects.
he weight of evidence from the present study (1) as well as the
eview of the available data (2) suggest that PP amplification
ntegrates the synergistic effect of known or potentially unknown
V risk factors on blood pressure and arterial wall structural and
unctional properties. Thus, this is not just a mathematical
ssociation but an association based on the pathophysiology of the
rterial disease. We agree with the view (3) that direct assessment
f PP amplification will possibly provide more solid results by
voiding mathematical controversies and less “dilution” of the
iophysical mechanisms. Our goal was not to provide evidence in
erms of methodological gold-standard precision (e.g., by receiver
perator characteristics curves analysis) but in terms of pathophys-
ological applicability.
Certainly as suggested (3), biomedical innovation on the field is
arranted. The confirmation of the validity of the present model
nd results using other methodologies and population by the group
f Philadelphia would also be of great help.
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evices Created Equal?
e read with interest the 15-month follow-up of the DEDICATION
Drug Elution and Distal Protection in Acute Myocardial Infarc-
ion) trial reported by Kaltoft et al. (1). The authors find that, in
atients undergoing primary percutaneous coronary intervention
pPCI) randomized to receive distal protection (DP) with embolic
lter devices, the rates of stent thrombosis and both clinically
riven target lesion revascularization (TLR) and target vessel
evascularization (TVR) were significantly higher than in patients
andomized to standard pPCI. This finding is perhaps not so
urprising when the physical characteristics of the devices used and
ecognized complications of their use are considered.
The majority of DP devices used in the trial were FilterWire EZ
evices (Boston Scientific, Natick, Massachusetts), whereas a
maller proportion of patients in the study received the SpiderX
evice (eV3 Inc., Minneapolis, Minnesota); this device has the
dvantage of being available in a variety of different sizes that may
e tailored to the patient’s particular coronary anatomy. The
ilterWire EZ, however, is available in only 1 size, designed for
essel reference diameters between 3.5 and 5.5 mm. The median
essel diameter and the diameter of stent deployed in the patients
eceiving DP devices were 3.5 mm, implying therefore that a
ubstantial proportion of patients receiving such devices had native
essel reference diameters smaller than the minimum vessel size
esignated for the FilterWire EZ.
Furthermore, even when appropriately sized, the FilterWire EZ
as been demonstrated to cause histological evidence of substantial
ntimal disruption (2), and simple extrapolation might indicate
hat an oversized device may lead to deeper medial injury similar to
hat observed in experimental models of deliberate vascular injury
eading to predictably observed restenosis (3).
Therefore, the findings of the study in terms of the increased
ates of restenosis that presumably led to observed higher rates of
LR and TVR (1) may be explained by the utility of devices
versized for target vessel pPCI. Further analysis of the differences
n TLR/TVR rates in patients receiving the different types of
evices would therefore be informative and, although numbers in
he study may be relatively small, might further inform the debate
s to whether DP devices should be barred outright in pPCI, or
lternatively that appropriately sized DP devices may still have
ome utility.
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